Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(12/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(12/week)
News
United States
(492/week)
Manufacturing
(332/week)
Energy
(271/week)
Technology
(348/week)
Other Energy
(234/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Lenalidomide
Jun 12, 2020
EHA25Virtual: Promising Treatment Results with Imetelstat, a Novel Telomerase Inhibitor, in Patients with Lower Risk Myelodysplastic Syndromes
Jun 01, 2020
New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021
May 22, 2020
Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included
Mar 17, 2020
National Research Cancer Institute UK Confirms Benefit Molecular Profiling in Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Feb 10, 2020
Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
Feb 03, 2020
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
Jan 13, 2020
John Theurer Cancer Center Investigators Report Effectiveness of New Treatment for Refractory Multiple Myeloma
Jan 06, 2020
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
Dec 16, 2019
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
Dec 10, 2019
DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Dec 09, 2019
DARZALEX® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant
Dec 04, 2019
First Industry Datasets Submitted to ASH Research Collaborative Data Hub
Dec 04, 2019
International Myeloma Foundation Presents Research, Video Reports, Social Media Coverage at 2019 American Society of Hematology Meeting (ASH)
Nov 21, 2019
Catalent to Supply BeiGene's BTK Inhibitor BRUKINSA(TM) (zanubrutinib)
Page 1
››
Latest News
Apr 18, 2024
WEB Aruba Signs Water-as-a-Service® BOOT Agreement with Seven Seas Water Group
Apr 18, 2024
Aqua Virginia Earns State Excellence Award for 19th Consecutive Year
Apr 18, 2024
Aqua New Jersey Celebrates Completion of Newest PFAS Treatment Facility at its Green Avenue Well Station in...
Apr 18, 2024
Black Stone Minerals, L.P. Declares Distribution for Common Units and Schedules Earnings Call to Discuss...
Apr 18, 2024
HNI Corporation Receives DOE Better Project Award
Apr 18, 2024
The AZEK® Company Inc. Announces Fiscal Second Quarter 2024 Earnings Release and Investor Conference Call on...
Apr 18, 2024
Argonne’s Decarbonization Scenario Model Analyzes Ambitious Pathways to Net-Zero Carbon Emissions
Apr 18, 2024
Pinnacle West Declares Quarterly Dividend
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events